Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...

BAAR, Switzerland, May 31, 2025--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented ...

NEET PG 2025 exam date: The National Eligibility-cum-Entrance Test for Postgraduate courses (NEET PG) 2025 has been postponed and will now be held on August 3, 2025, following an extension granted ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab reduced the risk of progression or death by 48% in patients with ...

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.

Otsuka Pharmaceutical has shared more detailed data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio (UPCR) levels.

The NEET PG exam will be held on August 3 from 9 am to 12.30 pm. The result for the same will be announced on September 3, 2025. For more related details candidates can check the official website ...

a Formal significance testing was only performed at 52 weeks in the Phase 3 trials, with significance achieved for both the every two-week arm and every four-week arm in AERIFY-1 . The total number of ...

Prajakta Luthade, employee, Hinjewadi phase 3, said, “I have been working at a multinational corporation (MNC) in the Hinjewadi area for the past five years.

Over 200 patients were dosed, and 365 enrolled in the Nex-Z MAGNITUDE trial, aiming for 765 by early 2027. Intellia plans BLA filing for NTLA-2002 in HAE by late 2026, with a U.S. launch targeted ...

Novocure NVCR recently announced positive top-line results from its pivotal Phase 3 PANOVA-3 trial, evaluating Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab ...